Gonadotropin-releasing hormone antagonist: New tools vs. old habits

Fertility and Sterility

Volumn 73, Issue 1, 2000, Pages 18-20

  Bouchard, Philippe ^a   Fauser, Bart C J M ^b  

^a HÔPITAL SAINT ANTOINE   (France)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CETRORELIX; FOLLITROPIN; GANIRELIX; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; HUMAN MENOPAUSAL GONADOTROPIN; LUTEINIZING HORMONE;

FERTILIZATION IN VITRO; HUMAN; LUTEINIZING HORMONE RELEASE; OVULATION INDUCTION; PRIORITY JOURNAL; SHORT SURVEY;

EID: 0033971301     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0015-0282(99)00446-X     Document Type: Editorial

References (12)

1. Dubourdieu S., Charbonnel B., D'Acremont M.F., Carreau S., Spitz I.M., Bouchard P. Effect of administration of a gonadotropin-releasing hormone (GnRH) antagonist (Nal-Glu) during the preovulatory period the luteinizing hormone surge requires the secretion of GnRH . J Clin Endocrinol Metab. 78:1994;343-347.
2. Frydman R., Cornel C., de Ziegler D., Taieb J., Spitz I.M., Bouchard P. Prevention of premature luteinizing hormone and progesterone rise with a gonadotropin-releasing hormone antagonist, Nal-Glu, in controlled ovarian hyperstimulation. Fertil Steril. 56:1991;923-927.
3. Olivennes F., Alvarez S., Bouchard P., Franchin R., Salat-Baroux J., Frydman R. The use of a GnRH antagonist (Cetrorelix) in a single dose protocol in IVF-embryo transfer a dose finding study of 3 versus 2 mg . Hum Reprod. 13:1998;2411-2414.
4. Diedrich K., Diedrich C., Santos E., Zoll C., al-Hasani S., Reissmann T., et al. Suppression of the endogenous luteinizing hormone surge by the gonadotropin-releasing hormone antagonist Cetrorelix during ovarian stimulation. Hum Reprod. 9:1994;788-791.
5. Albano C., Smitz J., Camus M., Riethmuller-Winzen H., Van Steirteghem A., Devroey P. Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation. Fertil Steril. 67:1997;917-922.
6. A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotropin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle-stimulating hormone (Puregon). The ganirelix dose-finding study group. Hum Reprod. 13:1998;3023-3031.
7. Rongières-Bertrand C., Olivennes F., Righini C., Fanchin R., Taïeb J., Hamamah S., et al. Revival of the natural cycles in in-vitro fertilization with the use of a new gonadotropin-releasing hormone antagonist (Cetrorelix) a pilot study with minimal stimulation . Hum Reprod. 14:1999;683-688.
8. De Jong D., Macklon N.S., Fauser B.C.J.M. Minimal ovarian stimulation for IVF extending the FSH window . Jansen R., Mortimer D. Towards reproductive certainty? Fertility and genetics beyond 1999. 1999;195-199 Parthenon, New York.
9. Fauser B.C.J.M., Devroey P., Yen S.S.C., Gosden R., Crowley W.F. Jr, Baird D.T., et al. Minimal ovarian stimulation for IVF appraisal of potential benefits and drawbacks . [editorial] Hum Reprod. 14:1999;2681-2686.
10. Barbieri R.L., Hornstein M.D. Assisted reproduction-in vitro fertilization success is improved by ovarian stimulation with exogenous gonadotropins and pituitary suppression with gonadotropin-releasing hormone analogues. Endocr Rev. 20:1999;249-252.
11. Fauser B.C.J.M., Van Heusden A.M. Manipulation of human ovarian function physiological concepts and clinical consequences . Endocr Rev. 18:1997;71-106.
12. Kol S., Lightman A., Hillensjo T., Devroey P., Fauser B., Tarlatzis B., et al. High doses of gonadotropin-releasing hormone antagonist in in-vitro fertilization cycles do not adversely affect the outcome of subsequent freeze-thaw cycles. Hum Reprod. 14:1999;2242-2244.